Dyslipidemia is one of the most important cardiovascular disease (CVD) risk factors. Polyunsaturated fatty acids (FAs), and especially omega-3 FAs, could significantly contribute to the management of dyslipidemia and the prevention of CVD. The anti-hyperlipidemic effect of selected fish oils (eel, sardine, trout, cod liver) was comparatively evaluated in a high fat diet (HFD)-fed mouse model. At the end of 30 days on the HFD, all animals were hyperlipidemic and were switched to a diet consisting of 90% standard rodent chow plus 10% of oil from eel, sardine, cod liver, or trout. At the end of 60 days on these diets, blood glucose, total blood cholesterol, triglycerides (TGs), and high density lipoprotein (HDL) were quantitated. All diets, except sardine and standard rodent chow, showed statistically significant decreases in blood glucose from day 30 to 90. Total blood cholesterol decreased in all diets except the HFD group, which was continued on this diet until the end of the study. Eel and cod liver oil diets showed significant decreases in TGs. All dietary groups showed a decrease in HDL, but only the trout and standard chow groups exhibited statistically significant decreases. The fish oils tested here for effects on hyperlipidemia vary in per cent of omega-3 FAs and omega-6/-3 FA ratios as determined by gas chromatography Overall, smoked eel was the best source of omega-3 FA, with a balance of omega-6 FA, that ameliorated HFD-induced mixed hyperlipidemia.
Fatty Acids, Omega-3 , Hyperlipidemias , Animals , Eels , Fish Oils , Hyperlipidemias/drug therapy , Mice , Trout
The aim of the study was to examine the effect of operator experience on the quality of instrumentation of molar canals using the TF Adaptive file system (SybronEndo, Orange, CA) on a 3D-printed molar replica model. Three novice and two expert operators instrumented the root canals of three replicas each and resulting pre- and postinstrumentation 12 micron voxel size-microCT volumes of each replica were digitally registered. Relative modified canal wall surface fraction and canal transportation (1-9 mm from the apex) were calculated and analysed by anova. Instrumentation by expert operators resulted in overall higher (P = 0.002) modified wall surface fraction in the distal but not the mesial and higher (P = 0.002) combined from all canal level transportation in the mesiobuccal canals but not the mesiolingual and distal canals. Instrumentation efficiency but also transportation using the TF Adaptive file system can be higher among expert, compared to novice, operators, depending on the canal type.
Dental Pulp Cavity , Root Canal Preparation , Molar/diagnostic imaging , X-Ray Microtomography
Flow Cytometry , Neoplasm Recurrence, Local/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adolescent , Bone Marrow/pathology , Child , Child, Preschool , Disease-Free Survival , Female , Follow-Up Studies , Humans , Infant , Male , Neoplasm Recurrence, Local/pathology , Neoplasm, Residual , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Prognosis , Survival Analysis , Time Factors
Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Adolescent , Child , Child, Preschool , Disease Management , Female , Follow-Up Studies , Greece , Humans , Infant , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Treatment Outcome
BACKGROUND: Rabeprazole produces a profound and long-lasting inhibition of gastric acid secretion. The aim of the study was to monitor the safety and efficacy of rabeprazole administered to patients with erosive or symptomatic non-erosive reflux disease, in real-life healthcare settings. METHODS: Male and female patients, aged ≥18 years, with endoscopy diagnosed GERD were included; patients received at least 8 weeks treatment with rabeprazole. Changes in severity of symptoms recorded on the Likert scale were analysed using marginal homogeneity tests. RESULTS: 186 patients were enrolled across 17 study sites; 127 patients (68.3%) completed the study. Almost 75% of patients had an initial diagnosis of GERD with Grade A or B esophagitis. The most commonly reported adverse events (AEs) were diarrhea, flatulence, dizziness, cough, abdominal pain, upper abdominal pain and somnolence. Over half of AEs were unrelated to study drug; 1 severe AE of diarrhea was possibly related to study drug. No new AEs were reported not included in the current version of Summary of Product Characteristics. Rabeprazole was effective in reducing the symptoms of GERD; the Likert scale scores of symptoms decreased significantly for all patients from 0-4 weeks and 4-8 weeks. CONCLUSIONS: In our study, rabeprazole was safe and effective in reducing the symptoms of GERD.
